



Cell or tumor		:Cluster of differentiation antigen (CD)
Mature	B-cell markers	CD19, CD79, and CD20
	T-cell markers	CD3 (either CD4 or CD8)
Blast	marker of early lymphoid origin (B & T lymphoblasts)	TdT
Blast ALL	Pre-B cell (ALL)	<ul style="list-style-type: none"> <li>▷ Hyperdiploidy (&gt; 50</li> <li>▷ t(12;21).</li> <li>▷ t(9;22) involving ABL &amp; BCR genes.</li> </ul>
	Pre-T cell (ALL)	<ul style="list-style-type: none"> <li>▷ NOTCH1 mutations chromosomes/cell)</li> <li>▷ CDKN2A mutations</li> </ul>
	Worse prognosis	<ul style="list-style-type: none"> <li>▷ Younger than 2</li> <li>▷ Older than 10</li> <li>▷ PB WBC count &gt; count 100,000</li> <li>▷ t(9;22)</li> </ul>
	Favorable prognosis	<ul style="list-style-type: none"> <li>▷ Age between 2-10</li> <li>▷ PB Low WBC</li> <li>▷ Hyperdiploidy</li> <li>▷▷ t(12;21)</li> </ul>
CLL/SLL	<ul style="list-style-type: none"> <li>• If PB involvement count exceeds 5000 cells/μL</li> <li>• CD5</li> </ul>	
Follicular	<ol style="list-style-type: none"> <li>1. (14;18) translocation</li> <li>2. B-cells markers (mature B cell neoplasm)</li> <li>3. CD10 -&gt; GC marker</li> </ol>	
Mantle	<ol style="list-style-type: none"> <li>1. (11;14) translocation</li> <li>2. B cell markers</li> <li>3. CD5</li> </ol>	
Extranodal Marginal Zone Lymphoma	. B-cell markers.	
Diffuse Large B Cell Lymphoma	<ol style="list-style-type: none"> <li>1. Mutations &amp; rearrangements of the BCL6 gene -&gt; increased levels of BCL6 protein</li> <li>2. BCL6 protein, an important transcriptional regulator of gene expression in GC B-cells</li> <li>3. CD10</li> <li>4. B-cell markers</li> </ol>	
Burkitt Lymphoma	<ol style="list-style-type: none"> <li>1. translocations involving MYC gene on chr. 8 [master regulator of Warburg metabolism (aerobic glycolysis)] [The fastest growing human tumor]</li> <li>2. CD10</li> <li>3. B-cell markers</li> </ol>	
Hodgkin Lymphoma	In Classic:	Typical RS cells : 1- express CD15 2- express CD30 3- fail to express B-cell & T-cell markers.
	n NLP HL	RS variant cells: 1- express B cell markers (e.g., CD20) 2- fail to express CD15 and CD30
	Both	RS cells express high levels of PD ligands -> factors that antagonize T cell responses. (inhibit T cell function)
Mycosis Fungoides and Sézary Syndrome	<ol style="list-style-type: none"> <li>1- CD4 +T cells home to the skin.</li> <li>2- CD8 -</li> </ol>	
	only SLL & MCL express it)	CD5
	expressed in Burkitt lymphoma, B- ALL & some DLBCL)	CD10 [?] GC marker

Cell or tumor	Histology
Blast ALL	<ol style="list-style-type: none"> <li>scant basophilic cytoplasm and nuclei</li> <li><b>delicate, finely stippled chromatin</b></li> <li>small nucleoli</li> </ol>
CLL/SLL	<ol style="list-style-type: none"> <li><b>“soccer ball” appearance</b>: small lymphocytes with dark, round nuclei, <b>clumped chromatin</b> &amp; scanty cytoplasm</li> <li><b>prolymphocytes</b>: large lymphocytes with prominent centrally located nucleoli</li> </ol>
Follicular	<ol style="list-style-type: none"> <li>Lymph nodes usually are effaced by a distinctly nodular (follicular)</li> <li>Two types of neoplastic cells: <ol style="list-style-type: none"> <li>the predominant called <b>centrocytes</b> have angular “cleaved” &amp; indistinct nucleoli</li> <li>the other <b>centroblasts</b>, larger cells with vesicular chromatin, several nucleoli</li> </ol> </li> </ol>
Mantle	<ol style="list-style-type: none"> <li>composed of cells resembling the naive B cells found in the mantle zones of normal lymphoid follicles.</li> <li>The tumor cells are slightly larger than normal lymphocytes</li> <li>with irregular nucleus, inconspicuous (not clear) nucleoli</li> <li><b>sometimes arises in the GIT as multifocal polyps (lymphomatoid polyposis).</b></li> </ol>
Extranodal Marginal Zone Lymphoma	<ol style="list-style-type: none"> <li><b>lymphoepithelial lesions</b> : B-cells characteristically infiltrate the epithelium of involved tissues (in small aggregates)</li> <li>tumor arises most commonly in epithelial tissues (e.g. GIT, salivary glands, lungs,..)</li> <li>tumor cells accumulate <b>abundant pale cytoplasm or exhibit plasma cell differentiation</b></li> <li>example of a cancer arises within &amp; is sustained by chronic inflammation: <ol style="list-style-type: none"> <li>autoimmune disorders (salivary gland in Sjögren syndrome &amp; thyroid gland in Hashimoto)</li> <li>Chronic infection (such as H.pylori gastritis)</li> </ol> </li> <li><b>Ex: Gastric MZL (MALT lymphoma)</b></li> </ol>
Diffuse Large B Cell Lymphoma	<ol style="list-style-type: none"> <li>Diffuse infiltration by large neoplastic B cells (three to four times the size of resting lymphocytes)</li> <li>vary in appearance</li> </ol>
Burkitt Lymphoma	<ol style="list-style-type: none"> <li>“starry sky” pattern: These benign macrophages often are surrounded by a clear space</li> <li>Intermediate size lymphocytes (Variable cytoplasm, several nucleoli).</li> <li>numerous mitoses &amp; tissue macrophages containing ingested nuclear debris</li> <li>Very high rates of proliferation and apoptosis (high turnover)</li> </ol>
Hodgkin Lymphoma	<ol style="list-style-type: none"> <li>Reed-Sternberg (RS) cell: a very large cell with an enormous multilobate nucleus, exceptionally prominent nucleoli (inclusion-like) &amp; abundant cytoplasm.</li> <li>surrounded by a heterogeneous inflammatory infiltrate containing small lymphocytes, eosinophils, plasma cells, and macrophages.</li> <li>These characteristic nonneoplastic, inflammatory cells are generated by cytokines secreted by RS cells (IL-5, TGF-β, &amp; IL-13).</li> </ol>
Mycosis Fungoides Sézary Syndrome	<ol style="list-style-type: none"> <li>cerebriform appearance : infiltration of epidermis &amp; upper dermis by neoplastic T cells with marked infolding of the nuclear membranes</li> <li>tumor cells (Sézary cells) in the peripheral blood</li> <li>generalized exfoliative erythroderma</li> </ol>

Cell or tumor	Presentation
Blast ALL	<ol style="list-style-type: none"> <li>Symptoms related to depression of marrow function; anemia, neutropenia &amp; bleeding.</li> <li>Mass effects [?] neoplastic infiltration; bone pain</li> <li>CNS manifestations headache, vomiting, and nerve palsies.</li> <li><b>Aggressive but curable (85% cure rate in children)</b></li> <li>Neoplasms composed of immature B (pre-B) or T (pre-T) cells [?] called Lymphoblasts</li> <li>85% B-cells, commonly manifest as acute LEUKEMIA The most common cancer of children (Peak : 3 years)</li> <li>15% T-cells, commonly manifest as thymic LYMPHOMA Peak: adolescence</li> <li>In pre-B &amp; pre-T ALLs the blasts are identical in routine stains (immunophenotype is needed)</li> </ol>

Cell or tumor	Presentation
CLL/SLL	<ol style="list-style-type: none"> <li>Often asymptomatic</li> <li>But symptoms are nonspecific; easy fatigability, weight loss, anorexia, generalized lymphadenopathy &amp; hepatosplenomegaly.</li> <li>10-15% develop autoimmune hemolytic anemia &amp; thrombocytopenia.</li> <li>An indolent, slowly growing tumor {increased tumor cell survival is more important than tumor proliferation} {cure may only be achieved with hematopoietic stem cell transplantation (HSCT)}</li> <li>CLL &amp; SLL are essentially identical.</li> </ol>
Follicular	<ol style="list-style-type: none"> <li>Older than 50</li> <li>Generalized painless lymphadenopathy</li> <li>Bone marrow is involved in 80% of cases</li> <li>40% transform into DLBCL</li> <li>Prolonged survival, not curable disease (indolent)</li> <li>dismal prognosis</li> </ol>
Mantle	<ol style="list-style-type: none"> <li>fatigue &amp; lymphadenopathy</li> <li>involving the bone marrow, spleen, liver, and (often) GIT.</li> <li>Moderately aggressive &amp; incurable. ▷ The median survival is 4-6</li> </ol>
Extranodal Marginal Zone Lymphoma	<ol style="list-style-type: none"> <li>Present as swelling of the salivary gland, thyroid or orbit or are discovered incidentally in the setting of H. pylori-induced gastritis.</li> </ol>
Diffuse Large B Cell Lymphoma	<ol style="list-style-type: none"> <li>Median &gt; 60 years of age (but Can occur at any age)</li> <li>Generalized lymphadenopathy</li> <li>Can occur in extranodal sites (GIT)</li> <li>An aggressive and rapidly fatal lymphoma if not treated</li> <li>50% cure with treatment.</li> </ol>
Burkitt Lymphoma	<ol style="list-style-type: none"> <li>The fastest growing human tumor!!</li> <li>Both types affect children &amp; young adults.</li> <li>Usually arises at extranodal sites: <ol style="list-style-type: none"> <li>Endemic (?) maxillary or mandibular masses,</li> <li>Sporadic (?) abdominal tumors (bowel &amp; ovaries)</li> </ol> </li> <li>Highly aggressive; can be cured with very intensive chemotherapy regimens</li> </ol>
Hodgkin Lymphoma	<ol style="list-style-type: none"> <li>they arise in a single lymph node or group <ol style="list-style-type: none"> <li>Cervical and mediastinal</li> <li>Rarely tonsils, Waldeyer ring or extranodal sites</li> </ol> </li> <li>spread in a stepwise fashion to anatomically contiguous nodes.</li> <li>major subtypes <div data-bbox="379 1415 833 1589" style="border: 1px solid black; padding: 5px; margin: 5px 0;"> <p>▷ Classic HL</p> <ul style="list-style-type: none"> <li>▷ Nodular sclerosis</li> <li>▷ Mixed cellularity</li> <li>▷ Lymphocyte-rich</li> <li>▷ Lymphocyte-depleted</li> </ul> <p style="text-align: right;">} The two most common forms</p> <p>▷ Nodular lymphocyte predominant HL (NLP HL)</p> </div> </li> <li>Manifests as painless lymphadenopathy</li> <li>advanced disease (stages III &amp; IV) are more likely to exhibit <ol style="list-style-type: none"> <li>B symptoms (fever, weight loss, night sweats)</li> <li>pruritus &amp; anemia.</li> </ol> </li> <li>is very good, the 5- year survival rate for patients with stage 1-2 disease is more than 90%.</li> </ol>
Mycosis Fungoides Sézary Syndrome	<ol style="list-style-type: none"> <li>form of cutaneous T cell lymphoma.</li> <li>Usually manifests in three stages: <ol style="list-style-type: none"> <li>A nonspecific erythrodermic rash (patches)</li> <li>Progresses in time to a plaque phase.</li> <li>A tumor phase.</li> </ol> </li> <li>Sézary syndrome: a clinical variant of MF characterized by: <ol style="list-style-type: none"> <li>generalized exfoliative erythroderma</li> <li>tumor cells (Sézary cells) in the peripheral blood</li> </ol> </li> <li>Patients diagnosed with early- stage MF survive for many years.</li> <li>Patients with tumor- disease, visceral disease, or Sézary syndrome survive on average for 1-3 years.</li> </ol>